<?xml version="1.0" encoding="UTF-8"?>
<p id="p0125">While previous studies on remdesivir are promising, formal clinical evaluation is strongly warranted. In general, there are many reasons why favorable preclinical data can fail to translate directly into human clinical trial results [
 <xref rid="bb0230" ref-type="bibr">46</xref>], such as inadvertent use of irrelevant models, inability to achieve effective serum drug concentrations in patients, or the occurrence of unanticipated severe adverse events among patients. Therefore, postulating on expected results of the trials is extremely challenging.
</p>
